These are the top-selling anti-diabetes drugs in India

• According to Anand Rathi research, sales of diabetes drugs grew 9% in June alone.
  
• The changing preference of drugs by people has also had an impact on the Indian pharmaceutical industry with companies having stronger drug brands dealing with respiratory, cardiac and anti-diabetic therapies.
• An Anand Rathi research analysis shows that chronic therapies continue to lead growth in the pharma industry. “
  
  

Pharmaceutical giants across the world have witnessed higher sales in drugs related to respiratory, anti-diabetic, cardiac therapies due to coronavirus as compared to other drugs. This is because people with any comorbidities like diabetes and acute respiratory syndrome are at higher risk to COVID-19.

An Anand Rathi research analysis shows that chronic therapies continue to lead growth in the pharma industry. “In June, cardio grew 14% to `16bn (8% in Q1 FY21) and is now inching closer to becoming the largest therapy in India (MAT sales of `187bn vs. `189bn for anti-infectives). Other chronic therapies like diabetes grew 9%, and vitamin sales were up 6%,” the research noted.

Here’s a look at all the diabetes drugs with their sales data in the month of June —
Source: Anand Rathi research report


SEE ALSO:
The COVID-19 vaccine from Oxford and AstraZeneca shows 'promising' results in early human trials
From Intel and Wipro to TCS and Google— Here are the top job openings in the multinational companies
OnePlus Nord launch price, specs and more – Everything we know about the upcoming affordable OnePlus smartphone